Sarika Chandiramani
Sleep Medicine · Louisville, KYNPI 1760800031
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Veran Medical Technologies, Inc. at 52.4% of the total. Reporting peaked in 2019 at $1,012 and has fallen 69.1% since, to $312 in 2025.
Across 22 payments — averaging $79.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veran Medical Technologies, Inc.$912
- Inspire Medical Systems, Inc.$202
- Idorsia Pharmaceuticals US Inc$118
- Boehringer Ingelheim$113
- Genentech USA, Inc.$100
- Itamar Medical Inc$71
- plus $224 from 6 others
What the payments were for
- Travel & lodging$75643%
- Food & beverage$88451%
- Education$1006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veran Medical Technologies, Inc. | 3 | $912 |
| Inspire Medical Systems, Inc. | 4 | $202 |
| Idorsia Pharmaceuticals US Inc | 1 | $118 |
| Boehringer Ingelheim | 2 | $113 |
| Genentech USA, Inc. | 1 | $100 |
| Itamar Medical Inc | 1 | $71 |
| Insmed, Inc. | 2 | $56 |
| Jazz Pharmaceuticals Inc. | 3 | $50 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $38 |
| AstraZeneca | 1 | $27 |
| Viatris Specialty LLC | 1 | $27 |
| Stryker | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,740 in reported general payments places this provider in the 60th percentile of 28 sleep medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 22 | $380,882 |
| OfevNintedanib Esylate | 12 | $155,124 |
| WakixPitolisant Hcl | 14 | $92,142 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 102 | $78,153 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $17,878 |
| DuleraMometasone/Formoterol | 22 | $14,079 |
| EliquisApixaban | 22 | $13,716 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $8,772 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $8,740 |
| Spiriva RespimatTiotropium Bromide | 16 | $8,152 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $3,650 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,276 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,059 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $2,022 |
| Armodafinil | 11 | $731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $113 | $163,27628 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $27 | $20,93732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 28 sleep medicine providers in Kentucky.
Other sleep medicine in Louisville
- Kevin TriceLouisville$220K
- William LacyLouisville$6K
- Robert KarmanLouisville$3K
- Egambaram SenthilvelLouisville$2K
- Juhee MianLouisville$2K
- Nicole ToddLouisville$2K
- Ammar AlmasalkhiLouisville$2K
- Warren ShaikunLouisville$1K
- Rajanna RamaswamyLouisville$1K
- Courtney MinorLouisville$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.